Litcius/Paper detail

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Mark Lebwohl, Craig L. Leonardi, Nehal N. Mehta, Alice B. Gottlieb, Alan M. Mendelsohn, Jeff Parno, Stephen J. Rozzo, Alan Menter

2020Journal of the American Academy of Dermatology27 citationsDOI

Topics & Concepts

MedicinePsoriasisInternal medicinePsoriasis Area and Severity IndexPost-hoc analysisMetabolic syndromeAdverse effectDermatologyObesityPsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsSkin Diseases and Diabetes
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) | Litcius